OBJECTIVES The Swedish national payer, TLV, was interested in understanding how OLAI is used in routine clinical practice regarding dosing and its impact on psychiatric-related hospitalization. METHODS Three Swedish nationwide health registers: the patient register, the drug register and the mortality register were linked. Patients with ≥1 prescription of OLAI and one diagnosis of schizophrenia or schizoaffective disorder prior to initiation of OLAI were included in this retrospective patient mirror-image study. The minimum follow-up was six months. The study period was from 03/2010 until 12/2011. The average number and duration of hospitalizations were compared before and after initiation with OLAI using a Student’s t-test. RESULTS